

1 **The Natural History of Untreated Pulmonary Tuberculosis in Adults: A Systematic Review and Meta-** 2 **Analysis**

3 4 **Authors**

5 Bianca Sossen (MBChB)^{1,2,#}, Alexandra Richards (MMathPhys)^{3,4,#}, Torben Heinsohn (BMCh)^{2,5}, Beatrice
6 Frascella (MD)⁶, Federica Balzarini (MD)⁶, Aurea Oradini-Alacreu (MD)⁶, Prof. Anna Odone (PhD)⁷,
7 Ewelina Rogozińska (PhD)⁸, Brit Häcker (Dr)⁹, Prof. Frank Cobelens (PhD)^{10,11}, Prof. Katharina Kranzer
8 (PhD)¹²⁻¹⁴, Prof. Rein MGJ Houben (PhD)^{3,4;&}, Hanif Esmail (PhD)^{2,8,15;&,*}

9
10 ¹ Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa

11 ² Institute for Global Health, University College London, London, UK

12 ³ TB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, London, UK

13 ⁴ Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Public Health, London
14 School of Hygiene and Tropical Medicine, London, UK

15 ⁵ Helmholtz Centre for Infection Research, Department of Epidemiology

16 ⁶ School of Public Health, Vita-Salute San Raffaele University, Milan, Italy

17 ⁷ Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy

18 ⁸ MRC Clinical Trials Unit at University College London, UK

19 ⁹ German Central Committee against Tuberculosis (DZK), Berlin, German

20 ¹⁰ Amsterdam University Medical Centers location University of Amsterdam, Department of Global Health

21 ¹¹ Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands

22 ¹² Clinical Research Department, Faculty of Infectious and Tropical Disease, London School of Hygiene and
23 Tropical Medicine, London, UK

24 ¹³ Biomedical Research and Training Institute, Harare, Zimbabwe

25 ¹⁴ Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich,
26 Germany

27 ¹⁵ Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and
28 Molecular Medicine, University of Cape Town, South Africa

29

30 # Contributed Equally

31 & Contributed Equally

32 ¥ Corresponding Author: Dr Hanif Esmail at MRC Clinical Trials Unit, 90 High Holborn, London, WC1V

33 6LJ or h.esmail@ucl.ac.uk

34

35 **ABSTRACT**

36 **BACKGROUND**

37 Key stages in TB disease can be delineated by radiology, microbiology and symptoms, but transition
38 between relevant stages remains unclear. We sought to quantify progression and regression across the
39 spectrum of TB disease by systematically reviewing studies of individuals with untreated TB undergoing
40 follow up.

41 **METHODS**

42 We searched PubMed, EMBASE and Web of Science until December 31st 1960, the Index Medicus
43 between 1895 and 1945, and extensive investigator collections without date restriction - in English and
44 German. Eligible studies were observational cohorts and clinical trials, presenting adults/adolescents with
45 TB or recent TB exposure, undergoing follow-up for at least 12 months without therapeutic intervention.
46 Two authors independently reviewed titles/abstracts and full texts for inclusion. Quality was assessed with a
47 modified Newcastle-Ottawa Score, excluding highly biased studies. Summary estimates were extracted to
48 align with TB disease transitions in a conceptual model, and we used meta-analysis of proportions with
49 random-effects to synthesise the extracted data. This study is registered with PROSPERO
50 (CRD42019152585).

51 **FINDINGS**

52 10477 titles were screened and 1648 full texts reviewed. 223 met inclusion criteria. 109 were excluded for
53 high risk of bias and 90 did not have extractable data. 24 studies (34 cohorts) were included. Progression
54 from microbiologically negative to positive disease in those with radiographic TB evidence occurred at an
55 annualized rate of 9.71% (95% CI:6.17-13.34) with “active” TB imaging, and 1.06% (95% CI:0.31-1.82)
56 with “inactive” TB imaging. Reversion from microbiologically-positive to -undetectable in prospective

57 cohorts occurred at an annualized rate of 12.40% (95% CI: 6.81-17.99). Studies reported symptoms poorly
58 not allowing for direct estimation of transitions for subclinical (asymptomatic, culture positive) disease.

59 **INTERPRETATION**

50 We present the risk of progression in those with radiographic evidence of disease and the rate of self-cure
51 for microbiologically positive disease to inform global disease burden estimates, clinical guidelines and
52 policy decisions.

53

54 INTRODUCTION

55 Despite a clinical awareness of tuberculosis (TB) for centuries, its natural history is incompletely
56 understood. We have oscillated between characterizing TB with binary states of latent infection and active
57 disease, to a condition existing on a dynamic continuum(1–4). In the early 20th century, TB control relied
58 on early identification of those with evidence of disease, particularly through chest X-ray (CXR) screening.
59 Researchers were able to highlight the heterogeneity and dynamics of disease evolution between individuals,
60 through longitudinal assessment(5–8). With the discovery of effective treatment in the mid-20th century and
61 driven by the need for scalable, programmatic treatment algorithms, a binary description of disease states
62 reflecting two extremes (‘latent infection’ and ‘active disease’) became established(9). Although this
63 provided a useful paradigm, the more nuanced understanding of disease natural history was arguably
64 forgotten.

65
66 An accurate understanding of the kinetics of TB natural history is now increasingly critical at both
67 population and individual level, with implications for disease management, population-level prevention and
68 control, and disease burden estimations. Treatment of patients that fall between active and latent TB - for
69 instance having abnormalities suggestive of active disease on X-ray but microbiologically negative - is not
70 adequately covered by management algorithms, but progress could be driven by adequate understanding of
71 the risk of disease progression. A better understanding of this natural history is also a key priority for
72 vaccine development(10). In addition, estimates of TB burden currently rely strongly on assumptions around
73 the progression, regression and mortality from untreated TB, of which only mortality estimates are informed
74 by systematic review of available literature(11–13). Furthermore, estimation methods do not cater to
75 different stages of TB which are detected in disease prevalence surveys, including individuals who have
76 culture positive disease but a negative symptom screen (referred to as subclinical), or those with TB
77 suggestive X-rays(14). Given the implications for health care seeking and potential for interrupting or
78 preventing transmission, a better understanding of this natural history is key to inform TB burden estimation
79 and policies for care and prevention.

80

Within the disease continuum, key stages in the evolution of pulmonary TB can be marked by diagnostic tests that have been available for over a century, to allow for categorization within a widely accepted conceptual framework (Figure 1)(1,2). The emergence of disease pathology is first visible by typical radiographic features. Microbiological detection in sputum signals presence of bacilli (and potential infectiousness), and the reporting of symptoms marks the development of active, clinical disease. Transitions across all of these stages can only be fully studied in the absence of treatment and hence can no longer be ethically investigated. We conducted a systematic review focusing on articles from the pre-chemotherapy era to determine which of the transitions could be adequately described by existing literature, with the aim of providing parameters for the rate of progression and regression of disease across the spectrum.




Figure 1: Conceptual framework of transitions occurring in the natural history of tuberculosis

The design of this conceptual framework is based on the available literature regarding the natural history of TB, where a subclinical group is included(1,15,16). The figure demonstrates that individuals would undulate between states of having (1) normal chest x-ray, negative microbiology and being asymptomatic, to (2) chest x-ray abnormalities, but still having negative microbiology and being asymptomatic, to (3) chest x-ray abnormalities with positive microbiology but being asymptomatic, to (4) chest x-ray abnormalities with positive microbiology and being symptomatic. We recognize individuals do not always fall into these groupings while transitioning along the spectrum of disease, for example an individual may present with an abnormal chest X-ray and symptoms that may represent TB but have negative microbiology. We have made allowances to capture all combinations of CXR, microbiology and symptoms status within the review.

CXR=Chest X-ray; Micro=Microbiology; Symp=Symptoms

Panel: Research in context

Evidence before this study

Certain aspects of the natural history of TB in the absence of treatment have been previously estimated through systematic review of the literature. Several authors have assessed the progression of latent infection (defined by TST or Interferon-gamma releasing assay (IGRA)) to active disease (usually defined by bacteriological positivity). However, these studies took a binary approach to categorizing TB, not recognizing the spectrum of disease states. Tiemersma *et al* took a systematic approach to determine the mortality of untreated TB disease distinguishing the outcome of ‘open’ and ‘closed’ disease, interpreted as smear positive and smear negative disease respectively. However, they did not focus on the dynamics of progression and regression of early stages of disease. Marais *et al* have investigated the natural history of TB in childhood, focusing on age specific rates and nature of disease progression following primary infection in children. Key gaps in our understanding of disease natural history therefore remain to be systematically assessed. Most notably, in individuals with changes consistent with early TB on CXR (as found on national prevalence surveys), the risk of progression to bacteriologically positive disease has not been sufficiently summarized, nor do we know the progression and regression from bacteriologically positive, symptom screen negative disease, or adequately understand regression (or ‘self-cure’) from classic ‘active disease’, i.e. bacteriologically positive, symptom screen positive.

Added value of this study

This systematic review has used the enormous body of historical literature to better capture progression and regression across the spectrum of TB disease stages: defined by chest imaging, sputum microbiology and symptom status. We identified 34 cohorts with a combined sample of 139,212 participants that contributed to our analysis. We show progression to bacteriologically positive disease of 10%/year from individuals with CXRs suggestive of active TB, and quantify reversion (self-cure) from microbiologically-positive disease, but could not directly quantify progression into and regression from subclinical disease

Implications of all the available evidence

With the currently available and newly generated evidence, we have a better understanding of the kinetics of TB natural history. High progression from CXR positive disease calls for a reconsideration of treatment guidelines. In addition, the comprehensive data collected could enable modelling to inform kinetics around subclinical disease as well. Finally, this improved understanding will allow for efforts to be refined when attempting to study and improve diagnostic and prognostic biomarkers, and likely allow for greater benefit to be derived from targeted TB prevention and treatment efforts.

l6

l7

18 **METHODS**

19

20 **Search strategy and selection criteria**

21 This systematic review and meta-analysis was conducted following a protocol registered at PROSPERO
22 (CRD42019152585). The study is reported in accordance with the Preferred Reporting Items for Systematic
23 Reviews and Meta-analyses (PRISMA) guidelines(17). We searched for articles from the pre-chemotherapy
24 era combining electronic and manual searches. Electronic searches were conducted in Medline (via
25 PubMed), EMBASE and Web of Science from the start of the database (1946, 1947, and 1900 respectively)
26 until 31st December 1960, in two languages with high yield for study designs of interest in this period:
27 English and German. Additionally, we manually searched titles from Index Medicus between 1903 and
28 1945; volumes from 1895-1902 were not available. The systematic search was restricted to manuscripts
29 published prior to 1960 to include cohorts observed from the pre-chemotherapy era while allowing for a
30 publication delay of earlier cohorts. Furthermore, supplementary searches were conducted in extensive
31 author collections. Further references were snowballed from those articles that met the criteria for data
32 extraction and from key review articles. Personal libraries and snowballed references were searched without
33 date restriction.

34

35 Electronic search terms used both modern and historical terminology in English and German (full search
36 strategies in supplementary appendix). All titles were imported into Covidence systematic review software
37 (Veritas Health Innovation, Melbourne, Australia). After de-duplication, titles and abstracts were screened
38 for relevance by two independent reviewers, with a third reviewer resolving conflicts. Full text articles were
39 sought online, within the library stores at the Wellcome and British libraries (English articles) and the
40 library of the German Central Committee against Tuberculosis (DZK) and the German Tuberculosis Archive
41 (DTA) (German articles), and on online archive websites (e.g HathiTrust.org and archive.org). If
42 manuscripts could not be found through any of these sources, they were not included. At full-text stage, two
43 independent reviewers reviewed eligibility. Articles were included if they presented a longitudinal cohort of
44 at least 25 adolescents (≥ 10 years) and/or adults followed up (radiologically, microbiologically and
45 clinically) for at least 12 months from the point of either (1) positive TST following recent TB exposure, (2)

16 radiographic changes suggestive of TB or (3) positive microbiology for TB (smear microscopy and/or
17 mycobacterial culture). A minimum of 12 months was selected in order to ensure an adequate number of
18 events. Articles were excluded if they made no attempt at microbiological confirmation of disease, presented
19 no new data (i.e. review article), all participants received a therapeutic (medical or surgical) intervention or
20 those who did not receive a therapeutic intervention could not have data extracted separately, or where $\geq 5\%$
21 of the cohort were paediatric (<10 years) and these children could not be separated from the adolescent/adult
22 data.

23
24 Eligible articles were assessed for risk of bias with an adapted Newcastle-Ottawa Scale (NOS) to a
25 maximum of seven stars (NOS - General Quality Assessment) by two reviewers per language
26 (supplementary table 1) with conflicts resolved by consensus. To pass the quality assessment, studies could
27 only lose two stars in the “Study Selection” and “Outcome” domains of the NOS. The “comparability”
28 domain was not assessed as this systematic review did not use control groups. An additional quality
29 assessment tool was designed to assess the quality of specific diagnostic compartments in study cohorts i.e.
30 radiological, microbiological and symptoms (supplementary table 1). While this Specific Quality
31 Assessment was captured to get a sense of quality of the study designs, it did not inform study eligibility.
32 Those that passed the NOS were extracted in a standardized electronic tool by one reviewer and then
33 datapoints confirmed by a second reviewer with conflicts were resolved by consensus, involving input from
34 additional reviewers if needed.

35 36 **Data extraction and analysis**

37 We extracted data corresponding to the proportion of individuals in the cohort transitioning between
38 diagnostic states (figure 1) over a specified period of time. Recognizing that description of symptom status
39 in particular may not always be explicit by current standards this could be recorded as unknown as long as
40 microbiological status was clear. Where authors differentiated abnormal chest imaging that was suggestive
41 of TB versus not suggestive then we only extracted the TB-suggestive group as abnormal. In addition, where
42 authors provided a subgroup of abnormal chest x-rays that were limited to only calcified nodules then we

73 did not deem these to be an abnormal x-ray for the purpose of this review. The clinical classification method
74 of the National Tuberculosis Association Diagnostic Standards and Classification of Tuberculosis;
75 facilitated extraction of the data(18).

76

77 Certain studies presented the proportion of individuals who progressed within a window of time rather than
78 a specific time point; in these cases, we have presented datapoints as at the midpoint of the time window
79 provided. All summary estimates are presented with 95% confidence intervals, calculated from the point
80 data provided. To allow for exploration of the data and any heterogeneity, we attempted to collect data on
81 variables of interest, namely: age distribution, sex, frequency of follow up visits, microbiological test used
82 (i.e. culture versus smear), CXR characteristics described by the historical study's authors, TST data, local
83 disease burden as per today's WHO classification(19), features of the study design (i.e. passive versus active
84 versus mixed case finding and whether the data was generated from two cross-sectional assessments of
85 participants ("single follow-up") or through a cumulative count of events over time ("cumulative count")),
86 the enrollment setting, and symptom status.

87

88 To allow comparison of the varying follow-up times, the last data point of each study was annualised and
89 the expected number transitioning in the first year calculated. The variance of the annualised rate was then
90 calculated using the `escalc` function from the `metafor` package(20), specifying the raw proportion measure.
91 Meta-analysis was then conducted using the `rma` function with the study outcome and variance as inputs. By
92 default each study was weighted proportional to the inverse of the variance calculated in the previous step.
93 The forest plots were created using the `forest` function from the `meta` package. Confidence interval
94 proportions were limited to between 0 and 1 by the `observation limit` argument within the `forest` function.
95 Sub analyses were also conducted using the `rma` function and added to the forest plot using the `addpoly`
96 function from `metafor`. Heterogeneity was assessed with the I^2 and τ^2 statistics.

97

98 **Role of the funding source**


9 The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or
0 writing of the report.

1

2

RESULTS

After de-duplication a total of 10477 titles and abstracts were screened of which 8829 were deemed not relevant (figure 2). 145/1648 (8.8%) full texts could not be sourced. A further 1280 studies were deemed to meet exclusion criteria, leaving 223 for bias assessment. A high risk of bias was found in 109 studies and an additional 90 could not reliably have data extracted and therefore did not contribute to our results. In total, 22 English and two German articles, with a combined sample of 139,212 participants contributed 34 cohorts for analysis. Eight of the 24 studies scored maximal scores on the General Quality Assessment. The quality of data on symptom status was generally poor, with 10 studies scoring zero stars in the Specific Quality Assessment (supplementary table 2).



12

13 **Figure 2: Study Selection**

14

15

16

17 The setting for the 34 longitudinal cohorts were as follows: workplace or university screening (n=5), general
18 community screening (n=7), from household contact studies (n=4), clinical cohorts at clinics or sanatoria
19 (n=9) and control arms of therapeutic interventions (n=9) (table 1 and supplementary table 3). Cohorts were
20 conducted in Europe (n=10), Asia (n=11), North America (n=11), Africa (n=1) and South America (n=1).
21 Eleven of the 34 cohorts provided an estimate of the local burden of TB disease in the study setting and
22 related time period. The majority (n=9/11) of these settings would be classified as endemic or high burden
23 TB settings, and the remainder (n=2/11) as medium burden, based on today's WHO classification(19).
24 Cohorts were conducted between 1923 and 2004 with 20/34 (58.8%) prior to 1960.

25
26 We did not identify any cohorts, meeting our inclusion and quality criteria, closely following up confirmed
27 recent TST converters where transition from normal chest X-ray (CXR) to CXR suggestive of TB was
28 reported. We identified four cohorts following up participants with normal radiography, negative
29 microbiological testing where the timepoint of initial infection was unclear, with either no evidence of
30 symptoms (n=3 (75.0%)) or unrecorded symptom status (n=1 (25.0%)) (table 1). We identified 24 cohorts
31 following-up participants with evidence of radiographic abnormalities and negative microbiology but with
32 either no symptoms (n=8 (33.3%)), symptoms (n=3 (12.5%)) or mixed/unknown symptoms (n=13 (54.2%))
33 initially. Of these 24 cohorts, the radiographic abnormalities were specified by the original authors as either
34 active (n=9 (37.5%)) or inactive/fibrotic (n=7 (33.3%)), with the remaining being mixed or not specified
35 (n=8 (29.1%)). We identified six cohorts following participants with microbiologically detectable
36 tuberculosis either initially with symptoms (n=4 (66.7%)) or those with an unknown symptom status (n=2
37 (33.3%)), however there were no cohorts found in which patients were documented to be asymptomatic.

8 **Table 1: Extracted studies**

	Cohort Years	Age distribution	Percentage Female	Local Burden of Disease; Setting	Study Type	Data Collection	Cohort Size (n)	Micro. quality (design*)	X-ray Description†	Follow up‡	Starting point§	Endpoint§
1. Alling(21)	1938 - 1948	Average: 52 years	Unknown	Not specified; USA	Clinic/Hospital/ Sanatorium cohort	Retrospective	58	Unclear (passive)	Inactive	Cumulative	cxr.pos micro.neg sympt.unk [arrested¶]	cxr.pos micro.pos sympt.unk
2. Anastasatu(22)	Publ : 1985	Unknown	Unknown	Not specified; Romania	Control/Placebo arm	Prospective	143	>1 culture (active)	Inactive	Cumulative	cxr.pos micro.neg sympt.neg	cxr.pos micro.pos sympt.unk
3. Aneja(23)	1975 - 1977	Minimum: 12 years	41.8	Not specified; India	Control/Placebo arm	Prospective	110	>1 culture (active)	Not specified	Single	cxr.pos micro.neg sympt.pos	cxr.pos micro.pos sympt.unk
4. Beuwkes(24)	1933 - 1938	Unknown	Unknown	Not specified; USA	Household Contact Study	Prospective	784	>1 culture (not specified)	Neg	Single	cxr.neg micro.neg sympt.neg	cxr.unk micro.pos sympt.pos
							79		Inactive	Single	cxr.pos micro.neg sympt.neg	cxr.unk micro.pos sympt.pos
							43		Active	Single	cxr.pos micro.neg sympt.pos	cxr.unk micro.pos sympt.pos
							28		Active	Single	cxr.pos micro.pos sympt.pos	cxr.unk micro.neg sympt.unk
5. Bobrowitz(25, 26)	1938 - 1945	Unknown	58	Not specified; USA	Clinic/Hospital/ Sanatorium cohort	Prospective	191	≥1 culture (passive)	Mixed	Single	cxr.pos micro.neg sympt.unk	cxr.pos micro.pos sympt.unk
6. Borgen(27, 28)	1947 - 1949	Minimum: 15 years	20.5	High; Norway	Occupational /Student Screening	Prospective	24	Unclear (active)	Active	Single	cxr.pos micro.neg sympt.pos	cxr.pos micro.pos sympt.pos
							120		Active	Single	cxr.pos micro.neg sympt.neg	cxr.pos micro.pos sympt.pos
7. Breu(29)	1949 - 1952	Minimum: 15 years	Unknown	Medium; Germany	General Community Survey	Prospective	904	>1 culture (active)	Mixed	Single	cxr.pos micro.neg sympt.unk	cxr.pos micro.pos sympt.unk
8. Cowie(30)	1979-1984	Unknown	0	Not specified; South Africa	Occupational /Student Screening	Prospective	152	>1 culture (passive)	Active	Cumulative	cxr.pos micro.neg sympt.unk	cxr.pos micro.pos sympt.unk
9. Downes(31)	1923 - 1935	Range: 15-69 years	50	Not specified; USA	Clinic/Hospital/ Sanatorium cohort	Retrospective	342	Microscopy Only (passive)	Active	Cumulative	cxr.pos micro.pos sympt.pos	cxr.pos micro.neg sympt.neg
10. Frimodt-Moller(32)	1960 - 1961	Minimum: 15 years	29	High; India	Control/Placebo arm	Prospective	86	>1 culture (active)	Active	Cumulative	cxr.pos micro.neg sympt.unk	cxr.pos micro.pos sympt.unk
11. Hong Kong Chest Service(33)	Publ : 1979-1981	Range: 15-75	30.68	Not Specified; Hong Kong	Control/Placebo arm	Prospective	176	>1 culture (active)	Active	Cumulative	cxr.pos micro.neg sympt.mix	cxr.pos micro.pos sympt.unk

36)												
12. IUAT Committee on Prophylaxis(37)	Publ ¹¹ : 1982	Average: 50 years	47	Not specified; Europe	Control/Placebo arm	Prospective	6990	>1 culture (active)	Inactive	Cumulative	cxr.pos micro.neg sympt.unk	cxr.pos micro.pos sympt.unk
13. Lincoln(38)	1937 - 1947	Minimum: 14 years Average: 24 years	49.8	Not specified; USA	Clinic/Hospital/Sanatorium cohort	Retrospective	314	Unclear (passive)	Inactive	Cumulative	cxr.pos micro.neg sympt.unk [arrested ¹¹]	cxr.pos micro.pos sympt.unk
14. Manser(39)	1941 - 1951	Range: 60-83 years	Unknown	Not specified; Switzerland	Clinic/Hospital/Sanatorium cohort	Retrospective	40	Unclear (active)	Active	Single	cxr.pos micro.pos sympt.unk	cxr.pos micro.neg sympt.unk
15. Marshall(40)	1947- 1948	Range: 15-30 years	59.6	Not specified; United Kingdom	Control/Placebo arm	Prospective	52	>1 culture (active)	Active	Cumulative	cxr.pos micro.pos sympt.pos	cxr.pos micro.neg sympt.unk
16. National Tuberculosis Institute(42-49)	1961 - 1968	Minimum: 5 years	49	High; India	General Community Survey	Prospective	31490	>1 culture (passive)	Neg	Single	cxr.neg micro.neg sympt.unk	cxr.pos micro.pos sympt.unk
							329	>1 culture (active)	Active	Single	cxr.pos micro.neg sympt.unk	cxr.pos micro.pos sympt.unk
							269	>1 culture (active)	Active	Single	cxr.pos micro.pos sympt.unk	cxr.pos micro.neg sympt.unk
17. Norregaard(50)	1978 - 1985	Minimum: 20 years	39	Medium; Denmark	Control/Placebo arm	Prospective	28	>1 culture (active)	Active	Cumulative	cxr.pos micro.neg sympt.mix	cxr.pos micro.pos sympt.neg cxr.pos micro.pos sympt.pos
18. Okada(51)	2002 - 2004	Minimum: 10 years Median: 30.6 years	54	High; Cambodia	General Community Survey	Prospective	309	>1 culture (active)	Active	Single	cxr.pos micro.neg sympt.neg	cxr.pos micro.pos sympt.unk
								>1 culture (passive)				cxr.pos micro.pos sympt.pos
								>1 culture (active)				cxr.neg micro.neg sympt.unk
							21580	>1 culture (passive)	Neg	Single	cxr.neg micro.neg sympt.neg	cxr.pos micro.pos sympt.unk
19. Orrego Puelma(52)	Publ ¹¹ : 1945	Minimum: 15	42	Not specified; Chile	Clinic/Hospital/Sanatorium cohort	Retrospective	67	>1 culture (passive)	Mixed	Single	cxr.pos micro.neg sympt.unk	cxr.pos micro.pos sympt.unk
20. Pamra(53)	1958 - 1968	Range: 15-45 years	11	Not specified; India	Control/Placebo arm	Prospective	178	>1 culture (active)	Inactive	Cumulative	cxr.pos micro.neg sympt.neg	cxr.pos micro.pos sympt.pos

												cxr.pos micro.pos sympt.neg
21. Puffer(54)	1931 - 1943	Unknown	60.6	Not specified; USA	Clinic/Hospital /Sanatorium cohort	Retrospective	261	>1 culture (passive)	Mixed	Single	cxr.pos micro.neg sympt.neg	cxr.pos micro.pos sympt.pos
							267		Inactive	Single	cxr.pos micro.neg sympt.neg [arrested [¶]]	cxr.pos micro.pos sympt.pos
							384		Active	Single	cxr.pos micro.pos sympt.pos	cxr.pos micro.neg sympt.neg
22. Sikand(55)	1952 - 1958	Minimum: 15 years	Unknown	Not specified; India	Occupational/ Student Screening	Prospective	167	Unclear (not specified)	Inactive	Cumulative	cxr.pos micro.neg sympt.unk	cxr.pos micro.pos sympt.unk
							152		Mixed	Cumulative	cxr.pos micro.neg sympt.unk	cxr.pos micro.pos sympt.unk
23. Styblo(56)	1961 - 1965	Minimum: 15 years	53	High; Czechoslovakia	General Community Survey	Prospective	73000	>1 culture (passive)	Neg	Cumulative	cxr.neg micro.neg sympt.neg	cxr.unk micro.pos sympt.pos cxr.unk micro.pos sympt.unk
24. Tuberculosis Society of Scotland(57,5 8)	1954 - 1959	Minimum: 15	38.95	Not specified; Scotland	Control/Placebo arm	Prospective	95	>1 culture (active)	Inactive	Single	cxr.pos micro.neg sympt.neg	cxr.pos micro.pos sympt.unk

* “Active” microbiological follow up refers to those that systematically tested at specified intervals (or attempted testing in those able to produce sputum). “Passive” microbiological follow up refers to those where results either relied only on screening of TB notification or clinical records, or if they only assessed microbiologically when clinical or radiological deterioration was noted

† Based on historical authors’ description/classification. Further descriptions of how the authors made these assessments are available in the supplementary material.

‡ “Single” follow up refers to those with two cross-sectional assessments of the group of participants, whereas “cumulative” refers to those studies which cumulatively captured events over time

§ Start and end points have three characteristics or states including radiological (i.e. cxr.neg or cxr.pos or cxr.unk), microbiological (i.e. micro.neg, micro.pos, micro.unk, or micro.mixed), and symptom status (i.e. sympt.neg, sympt.pos, sympt.unk or sympt.mixed). Within these, “neg” denotes negative, “pos” denotes positive, “unk” denotes unknown and “mix” denotes mixed

¶ This group were known to have been microbiologically positive on a prior occasion, then documented arrested disease, followed by a relapse

|| “Pub” denotes those studies where the years in which studies were conducted are not known and therefore publication year/s are listed instead

ATT=Antituberculosis Therapy; IUAT=International Union Against Tuberculosis; Micro.=Microbiology; USA=United States of America

50 **Progression to microbiologically positive disease in those with abnormal chest x-ray at baseline**

51 From the 24 cohorts with abnormal chest radiography but no evidence of *M. tb* on respiratory sampling at
52 baseline representing 11,185 participants, development of microbiologically-detectable disease occurred in
53 between 1.1 – 57.9% of individuals with half the studies reporting a follow-up of up to three years (range
54 12-156 months) (figure 3a). Considerable statistical heterogeneity was seen across cohorts ($I^2 = 97.3\%$,
55 $\tau^2=0.001$, $p<0.01$). We considered that the radiographic abnormalities categorized as active versus
56 inactive TB (as specified by the original authors; supplementary table 4) could represent distinct
57 pathological states contributing to clinical variability of studies. Therefore we did not pool these studies in
58 meta-analysis, but rather conducted stratified meta-analysis to describe the progression of these two states
59 separately. The annualized rate of transition from microbiologically negative to positive was 9.7% (95% CI:
60 6.2-13.3) for those in the nine cohorts described to have active changes on radiography compared to 1.1%
61 (95% CI: 0.3-1.8) for those in the seven cohorts with inactive changes (figure 3a). Over a three-year period,
62 this would equate to 26% (95%CI: 17-35) of those with active TB changes vs 3% (95%CI: 1-5) with
63 inactive TB changes progressing from microbiologically positive to negative disease. Statistical
64 heterogeneity in the active and inactive TB subgroups was lower than in all cohorts taken together, $I^2 =$
65 77.4% and $I^2 = 53.2\%$ respectively. The annual progression in cohorts with “mixed” radiographic changes
66 was 6.3% (95% CI: 1.5-11.1) - in between the values for inactive and active strata.


67
68 Out of 24 cohorts that contributed patients to this group, 18 (75%) used culture as part of microbiological
69 work-up and the remainder ($n=6/25$) did not specify the microbiological tests undertaken. Restricting this
70 analysis to the 18/24 cohorts explicitly using culture had little impact on these results (supplementary figure
71 1). Only 11 cohorts provided data on symptom status. Of the 9 cohorts described to have active TB changes
72 on radiography, three were in symptomatic individuals. Progression in this subgroup was at an annualized
73 rate of 11.74% (95% CI: 2.73-20.75) (supplementary figure 2). There was only one cohort describing active
74 TB changes on radiography in an asymptomatic group with the remainder unknown.

75

76 In the four cohorts following up those with no radiographic changes suggestive of any TB (table 1),
77 transition to microbiologically positive occurred at an annualized rate of 0.14% (95% CI: 0.11-0.17)
78 (supplementary figure 3a). In “single follow up” and “cumulative count” studies, those with active TB
79 changes showed similar annual progression (supplementary figure 4).

30


31



32

33 **Figure 3a: participants entering cohorts with abnormal chest X-rays and negative microbiology,**
 34 **transitioning to positive microbiology:** forest plot of the random effects meta-analysis of annualized rates
 35 (as described fully in methods section) with proportion and 95% confidence intervals for subgroups.
 36 Subgroups are as per the historical authors' provided data on radiographic classification being either
 37 "active", "inactive" or where the group was "mixed".

38



39

30 **Figure 3b: participants entering cohorts with positive microbiology, transitioning to negative**
 31 **microbiology:** forest plot of the random effects meta-analysis of annualized rates (as described fully in
 32 methods section) with proportion and 95% confidence intervals for subgroups, according to study design
 33
 34

35

06 **Regression to negative microbiology in those with positive microbiology at baseline**

07 Six cohorts followed a total of 1115 participants with evidence of *M. tb* in respiratory samples at baseline
08 and assessed the proportion transitioning to a microbiologically undetectable state without treatment or
09 intervention, with two thirds of studies reporting up to three years of follow up (range 6-26 months). The
10 majority of these cohorts included participants with limited or minimal disease on CXR - either due to this
11 being entry criteria into the original study or due to the eligibility criteria of this systematic review. No
12 studies were able to adequately describe symptom status of the participants. Three out of six were
13 retrospective cohorts from TB hospitals or sanatoria and three were prospective cohorts from general
14 community/household surveys or a placebo arm of a trial. In four of the six cohorts, culture was used to
15 assess microbiological status of participants while in two cohorts, both retrospective, either microscopy was
16 used or nature of microbiological investigations was not specified. With meta-analysis, this transition
17 occurred at an annualized rate of 18.3% (95% CI: 3.0-33.7) (figure 3b), but there was considerable
18 heterogeneity across these studies ($I^2 = 98.1\%$, $\tau^2=0.03$, $p<0.01$). We then restricted the meta-analysis to
19 prospective studies, hence removing the three retrospective hospital/sanatoria cohorts, where culture had also
20 not be used in two instances, and showed an annualized rate of 12.4% (95% CI: 6.8-18.0) with reduced
21 statistical heterogeneity $I^2 = 35.1\%$. Over three years this would equate to 33% (95% CI: 19-45) of those
22 initially with culture positive TB becoming culture negative.

23

14

15 **DISCUSSION**

16 This review is the first to systematically summarize key aspects of the kinetics of the natural history of
17 untreated tuberculosis in adults, outside of the rate of mortality, making full use of historical literature in
18 English and German. Through meta-analysis we provide estimates of the risk of progression to
19 microbiologically positive disease in those with initially negative microbiology at an annualized rate of
20 approximately 10% in those with “active” radiographic TB changes and 1% in those with “inactive” or
21 fibrotic changes. For comparison, progression was approximately 0.1% for those with normal CXRs, while
22 recognizing that this rate would be affected factors such as local burden of disease. In addition to this we
23 provided an estimate for the reversion from culture-positive disease to culture negative without treatment
24 (also referred to as ‘self-cure’) as 12.4% per year.

25

26 These results highlight that individuals with CXR changes suggestive of active TB but who are found to be
27 initially microbiologically negative are at considerable risk of disease progression. Guidance on how to
28 manage this group is often unsatisfactory with a tension between providing empirical treatment, or
29 monitoring for bacteriological progression which can be resource intensive or unfeasible in resource
30 constrained settings. Better understanding of the risk of disease progression provided by this study could
31 assist decision making and inform the planning of necessary clinical trials. In addition, our study is the first
32 to determine an estimate for this transition which will be of use to modellers wanting to understand the
33 implications on intervening in this population. We also have shown that approximately a third of those with
34 culture positive disease could revert to culture negative without treatment over a 3-year period. While this
35 may not inform clinical management, our results may refine parameters in models used to estimate disease
36 incidence from prevalence survey data where the probability of so-called “self-cure” needs to be factored in.
37 Our annual rate of approximately 12% provides empirical foundation to the slightly higher rates of 15% and
38 20% used by Dye to parameterize “self-cure” – which was informed by a review of literature although not
39 systematic(59,60).

40

41 We used a widely accepted conceptual framework to guide our data collection which required determination
42 of the microbiological, radiological and symptom status of participants over follow-up. We found that no
43 single study systematically recorded these three features over the entire course of disease from exposure to
44 final outcome. In addition we found that the recording of symptoms in these studies was not explicit,
45 particularly during follow up - meaning there was insufficient empirical data to directly determine the
46 trajectory around subclinical (asymptomatic, microbiologically positive) TB. Subclinical TB is a commonly
47 identified state through CXR-based active case finding but conducting contemporary natural history studies
48 to determine the rates of progression and regression would present ethical challenges with the availability of
49 treatment. However, the substantial additional data uncovered in this review should allow inference of the
50 kinetics around subclinical TB, which Richards *et al* have explored using a Bayesian framework to utilize
51 the information from all available data simultaneously(61).

52

53 There are several key limitations to consider when interpreting the findings of this systematic review. HIV is
54 a significant role-player in the epidemiology of TB in certain settings today and 22 of 24 of our studies were
55 set prior to the discovery of the virus. It is likely that people living with HIV progress along the disease
56 spectrum with different kinetics, also influenced by immune status (62–64). Secondly the nature of this
57 research question and the historical focus resulted in studies being included from a period spanning almost
58 80 years; over this time period, microbiological and radiographic methods evolved. However, from a
59 microbiological perspective included studies predominately used culture and where they did not, we
60 conducted sensitivity analyses. For radiology, even where studies used mass miniature radiography or
61 fluoroscopy for screening, findings were typically confirmed with conventional chest radiography which
62 informed data extraction. The majority of studies were conducted over fifty years ago, when socioeconomic,
63 health access, comorbidity distribution and prevalence of TB were likely very different to what they are
64 today. However, these study environments may to a certain extent remain representative of many
65 contemporary settings with a high TB burden.

56

57 There are also considerable methodological challenges in conducting a systematic review involving
58 historical research. It is notable that 1503/1648 (91.2%) of studies were retrieved for full text review,
59 however for 95 studies that met eligibility and bias criteria, manuscript style did not allow for data
70 extraction and authors could not be contacted for assistance. Although our work focused on the period 1895-
71 1960, through extensive investigator collections and snowballing of references we are confident we were
72 able to identify key literature post-1960 as evidenced by nearly half of our final 24 studies being after this
73 date.

74

75 Through our extensive review, we find that the natural history of TB is a dynamic, heterogenous process
76 which is not adequately represented by a single 'active disease' state, and quantified three key transitions.
77 Importantly, this review provides a much-needed foundation of empirical data for our ongoing re-discovery
78 of the complexity of TB natural history, enabling a grounding for new preconceptions or dogmas, and a
79 drive toward new clinical guidelines and policies for those suffering from TB.

30

CONTRIBUTORS

HE, RH, BS, AR, FC, and KK conceptualised the study protocol. BS, AR, TH, BF, FB, AO, and BH carried out the literature search and data collection. AR and BS carried out the statistical analysis and verified the final data with input and oversight from HE, RH and ER. BS wrote the first draft of the manuscript with input from AR, RH and HE. All authors subsequently reviewed and edited the manuscript. All authors had full access to the study data and had final responsibility for the decision to submit for publication.

DECLARATION OF INTERESTS

We declare no competing interests.

ACKNOWLEDGEMENTS

This work was funded by TB Modelling and Analysis Consortium (MAC), Medical Research Council (Grant ref: MR/V00476X/1) and the European Research Council (Starting Grant Action Number 757699). We would like to acknowledge Adrienne Burrough, Bridget Chivers and Rohisha Luchin for their assistance in performing the hand searches of Index Medicus and in collecting literature from various English libraries, and would like to thank the team of the German Tuberculosis Archives in Heidelberg for assisting with collection of German literature.

REFERENCES

1. Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. *Nat Rev Microbiol.* 2009 Dec;7(12):845–55.
2. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. *Clin Microbiol Rev.* 2018 Jul 18;31(4):e00021-18.
3. Gothi DGD. NATURAL HISTORY OF TUBERCULOSIS. *Indian J Tuberc Suppl.* 1978;25(2):13.
4. Behr MA, Kaufmann E, Duffin J, Edelstein PH, Ramakrishnan L. Latent Tuberculosis: Two Centuries of Confusion. *Am J Respir Crit Care Med.* 2021 Mar 24;rccm.202011-4239PP.
5. Squire JE. Prognosis in Pulmonary Tuberculosis. *Hospital (Rio J).* 1909;4.
6. Gillespie JR. Prognosis in pulmonary tuberculosis. *Br Med J.* 1928 Jun;1928(1):436–7.

7. Amberson JB, Jones JM. Prognosis and treatment in minimal pulmonary tuberculosis. XIIth Conf Int Union Tuberc. 1952;Report and co-reports on the second subject:1–19.
8. Dijkstra C. Results of a frequent and longlasting sputum examination of cultures, performed on 445 patients suffering from tertiary pulmonary tuberculosis. *Acta Tuberc Scand.* 1952;26:301–14.
9. World Health Organization. What is DOTS? A guide to understanding the WHO-recommended TB Control Strategy [Internet]. 1999. Available from: https://apps.who.int/iris/bitstream/handle/10665/65979/WHO_CDS_CPC_TB_99.270.pdf?sequence=1&isAllowed=y
10. Cobelens F, Suri RK, Helinski M, Makanga M, Weinberg AL, Schaffmeister B, et al. Accelerating research and development of new vaccines against tuberculosis: a global roadmap. *Lancet Infect Dis.* 2022 Apr;22(4):e108–20.
11. World Health Organisation. Global tuberculosis report 2019. 2019.
12. Glaziou P, Dodd P, Dean A, Floyd K. Methods used by WHO to estimate the global burden of TB disease. 2020 Oct 14;
13. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. *PLoS ONE.* 2011;6(4):e17601.
14. Frascella B, Richards A, Sossen B, Emery J, Odone A, Law I, et al. Subclinical tuberculosis disease - a review and analysis of prevalence surveys to inform definitions, burden, associations and screening methodology. *Clin Infect Dis.* 2020;43.
15. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. *Nat Rev Dis Primer.* 2016 Dec;2(1):16076.
16. Esmail H, Barry CE, Young DB, Wilkinson RJ. The ongoing challenge of latent tuberculosis. *Philos Trans R Soc B Biol Sci.* 2014 Jun 19;369(1645):20130437.
17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021 Mar 29;n71.
18. Long ER, Hopkins FD. History of Diagnostic Standards and Classification of Tuberculosis of the National Tuberculosis Association. *Am Rev Tuberc.* 1952 Apr;65(4):494–504.
19. World Health Organization. WHO global lists of high burden countries for tuberculosis (TB), TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB), 2021–2025: background document [Internet]. Geneva: World Health Organization; 2021 [cited 2021 Nov 22]. Available from: <https://apps.who.int/iris/handle/10665/341980>
20. Naike Wang. How to Conduct a Meta-Analysis of Proportions in R: A Comprehensive Tutorial. 2018 [cited 2021 Oct 18]; Available from: <http://rgdoi.net/10.13140/RG.2.2.27199.00161>
21. Alling D, Bosworth E, Lincoln N. The after-history of pulmonary tuberculosis: V. Moderately Advanced Tuberculosis. *Am Rev Tuberc.* 1955;71(4):519–28.
22. Anastasatu C, Berceea O, Corlan E. Controlled clinical trial on smear negative, x-ray positive new cases, with the view to establishing if and how to treat them. *Bull Int Union Tub.* 1985;60:108–9.
23. Aneja KS, Gothi GD, Samuel GER. Controlled study of the effect of specific treatment on bacteriological status of “suspect cases.” *Indian J Tuberc.* 1979;26:50–7.

24. Beeuwkes H, Hahn RG, Putnam P. A survey of persons exposed to tuberculosis in the household. *Am Rev Tuberc.* 1942;45(2):165–93.
25. Bobrowitz ID, Hurst A, Martin M. Minimal Tuberculosis; the prognosis and clinical significance of a sanatorium treated group. *Am Rev Tuberc.* 1947;56(2):16.
26. Bobrowitz ID, Hurst A. Minimal Tuberculosis: Problems in Roentgenologic Interpretation. *Radiology.* 1949 Apr;52(4):519–32.
27. Borgen L., Meyer SN., Refsum E. A preliminary report of tuberculin tests and mass chest surveys carried out in Aker. *Acta Tuberc Scand Suppl.* 1950;26:159–68.
28. Borgen L., Meyer SN., Refsum E. Mass photofluorography, tuberculin testing, and BCG vaccination in the district of Aker (Norway) 1947-49. *Acta Tuberc Scand.* 1951;25(4):327–55.
29. Breu K. [Public health x-ray diagnosis of closed pulmonary tuberculosis later proved contagious]. *Beitrag Zur Klin Tuberk Spezifischen Tuberk-Forsch.* 1954;111(5):437–44.
30. Cowie L, Langton ME. Diagnosis of sputum smear- and sputum culture-negative pulmonary tuberculosis. *SAMJ.* 1985;68:1.
31. Downes J. A Study of Mortality among Individuals with Active Pulmonary Tuberculosis. *Milbank Mem Fund Q.* 1938 Jul;16(3):304.
32. Frimodt-Moller J, Parthasarathy R, Thomas J. Results of treatment of non-bacillary tuberculosis in a domiciliary treatment programme,-a preliminary report. 1960;
33. Hong Kong Chest Service. SPUTUM-SMEAR-NEGATIVE PULMONARY TUBERCULOSIS CONTROLLED TRIAL OF 3-MONTH AND 2-MONTH REGIMENS OF CHEMOTHERAPY. *The Lancet.* 1979 Jun;313(8131):1361–3.
34. Hong Kong Chest Service. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. 1981;
35. Hong Kong Chest Service, Centre TR. A Controlled Trial of 2-Month, 3-Month, and 12-Month Regimens of Chemotherapy for Sputum-Smear-Negative Pulmonary Tuberculosis: Results at 60 months. *Am Rev Respir Dis.* 1984;6.
36. Hong Kong Chest Service, Tuberculosis Research Centre, Mad, British Medical Research Council. A study of the characteristics and course of sputum smear-negative pulmonary tuberculosis. *Tubercle.* 1981 Sep;62(3):155–67.
37. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various duration of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. *Bull World Health Org.* 1982;60(4):555–64.
38. Lincoln NS, Bosworth EB, Alling DW. The After-History of Pulmonary Tuberculosis - III: Minimal tuberculosis. *Am Rev Tuberc.* 1954;70(1):17.
39. Manser H. [Tuberculosis in aged and its course during sanatorium treatment]. *Schweiz Z Tuberk Rev Suisse Tuberc Riv Svizzera Della Tuberculosis.* 1953;10(2):65–82.
40. Medical Research Council. Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation. *BMJ.* 1948 Oct 30;2(4582):769–82.

41. National Tuberculosis Institute B. Tuberculosis in a rural population of South India: a five-year epidemiological study. *Bull World Health Organ.* 1974;51(5):473–88.
42. Chakaraborty, A K, Singh, H, Srikantan, K, Rangaswamy, K R, Krishnamurthy, MS, Stephen, J A. Tuberculosis in a rural population of South India: Report on five surveys. *Indian J Tuberc.* 1982;29(3):153–67.
43. CHAKRABORTY AK, GOTHI GD, DWARKANATH S, SINGH H. Tuberculosis mortality rate in a South Indian rural population. *Indian J Tuberc.* 1978;25(3):181–6.
44. Krishnamurthy V, Nair S, Gothi G. A comparison of new cases (incidence cases) who had come from different epidemiological groups in the population. *Indian J Tuberc.* 1978;25(3).
45. Gothi GD, Chakaraborty AK, Jayalakshmi MJ. INCIDENCE OF SPUTUM POSITIVE TUBERCULOSIS IN DIFFERENT EPIDEMIOLOGICAL GROUPS DURING FIVE YEAR FOLLOW UP OF A RURAL POPULATION IN SOUTH INDIA. *Indian J Tuberc.* 1978;25(2):9.
46. Krishnamurthy VV, Nair SS, Gothi GD, Chakaraborty AK. Incidence of Tuberculosis among newly infected population and in relation to the duration of infected status. *Indian J Tuberc.* 1976;23(1).
47. Gothi GD, Nair SS, Chakaraborty AK, Ganapathy KT. Five year incidence of tuberculosis and crude mortality in relation to non-specific tuberculin sensitivity. *Indian J Tuberc.* 1976;23(2).
48. Chakaraborty AK, Gothi GD. RELAPSES AMONG NATURALLY CURED CASES OF PULMONARY TUBERCULOSIS. *Indian J Tuberc.* 1976;23(1):6.
49. Chakaraborty AK. INTERPRETATION OF PHOTOFLUOROGRAMS OF ACTIVE PULMONARY TUBERCULOSIS PATIENTS FOUND IN EPIDEMIOLOGICAL SURVEY AND THEIR FIVE YEAR FATE. *Indian J Tuberc.* 1974;21:8.
50. Norregaard J. Abacillary pulmonary tuberculosis. *Tubercle.* 1990;71:35–8.
51. Okada K, Onozaki I, Yamada N, Yoshiyama T, Miura T, Saint S, et al. Epidemiological impact of mass tuberculosis screening: a 2-year follow-up after a national prevalence survey. :7.
52. Orrego Puelma H, Grebe G. Analysis of One Hundred Cases of Minimal Pulmonary Tuberculosis. *Dis Chest.* 1945 Sep;11(5):375–9.
53. Pamra SP, Mathur GP. Effects of Chemoprophylaxis on Minimal Pulmonary Tuberculosis Lesions of Doubtful Activity. *Bull World Health Org.* 1971;45(5):10.
54. Puffer RR, Stewart HC, Gass RS. Tuberculosis according to age, sex, family history, and contact. *Am Rev Tuberc.* 1945;51(4):295–311.
55. Sikand BK, Narain R, Mathur GP. Incidence of TB as Judged by Re-surveys. A study of Delhi Police. *Indian J Tuberc.* 1959;6(3):73–83.
56. Styblo K, Dajkova D, Kubik A, Langerova M, Radkovsky J. Epidemiological and Clinical Study of Tuberculosis in the District of Kolin, Czechoslovakia. *Bull World Health Org.* 1967;37:56.
57. Tuberculosis Society of Scotland. A controlled trial of chemotherapy in pulmonary tuberculosis of doubtful activity. *Tubercle.* 1958 Jun;39(3):129–37.
58. Scottish Thoracic Society. A controlled trial of chemotherapy in pulmonary tuberculosis of doubtful activity: Five year follow-up. *Tubercle.* 1963 Mar;44(1):39–46.

59. Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. *The Lancet*. 1998 Dec;352(9144):1886–91.
60. Dye C. *The Population Biology of Tuberculosis*. United Kingdom: Princeton University Press; 2015.
61. Richards A, Sossen B, Emery J, Horton K, Heinsohn T, Frascella B, et al. The natural history of TB disease - a synthesis of data to quantify progression and regression across the spectrum. *medRxiv*. 2021;
62. Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Coussens AK, et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. *Nat Med*. 2016 Oct;22(10):1090–3.
63. Lawn S, Kerkhoff A, Wood R. Progression of subclinical culture-positive tuberculosis to symptomatic disease in HIV-infected individuals. *AIDS*. 25(17):2190–1.
64. Oni T, Burke R, Tsekela R, Bangani N, Seldon R, Gideon HP, et al. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. *Thorax*. 2011 Aug 1;66(8):669–73.
65. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. *The Lancet*. 2011 Apr;377(9776):1495–505.